Objective: The aim of this study was to: (a) screen a large group of unselected patients with juvenile systemic lupus erythematosus for anti-aquaporin 4 antibodies (AQP4-Ab); (b) identify clinical and laboratory predictors of the presence of AQP4-Ab positivity in juvenile systemic lupus erythematosus. Methods: Sera from 90 patients with juvenile systemic lupus erythematosus were tested for the presence of AQP4-Ab using a cell-based assay. Demographics, clinical and immunological features, treatment received were summarized. Fisher's exact test was used to identify clinical predictors of positivity for AQP4-Ab. Results: Five of 90 (5.5%) patients tested positive for AQP4-Ab, all of which had neurological involvement, mainly transverse myelitis and optic neuritis. AQP4-Ab-positive patients were more likely to have neurological symptoms (P ¼ 0.002), less likely to experience dermatological manifestations (P ¼ 0.045), and less likely to have detectable anti-dsDNA antibodies (P ¼ 0.022). These patients were also more likely to have received anti-epileptic (P ¼ 0.023) and anti-coagulant (P ¼ 0.007) drugs. Conclusions: The findings of this study indicate that some patients with juvenile systemic lupus erythematosus develop antibodies against aquaporin-4 and may be at risk of developing a neurological clinical phenotype. We suggest that all juvenile systemic lupus erythematosus patients should be systematically screened for the presence of AQP4-Ab and this may help identify a high risk for neurological involvement in juvenile systemic lupus erythematosus. Lupus (2019) 28, 1243-1249.
Introduction
Aquaporin-4 (AQP4) is a water channel found on the foot processes of astrocyte cells in the brain and is also expressed in the renal tract, the gastrointestinal system, skeletal muscles, lung and blood system. 1, 2 In the central nervous system (CNS), AQP4 is involved in water movement, cell migration and neuroexcitation. 3 Antibodies are predominantly of the IgG1 subtype and bind three-dimensional conformational epitopes on the extracellular loops of AQP4. This produces astrocyte damage by complement-dependent cytotoxicity which leads to bloodbrain barrier disruption and cause leukocyte infiltration and cytokine release resulting in damage to oligodendrocyte, myelin and neurons. 3 Antibodies against AQP4 (AQP4-Ab) were first identified in 2005 in patients with neuroinflammation best now classified as having neuromyelitis optica spectrum disorders (NMOSDs). 1 These NMOSDs are a group of inflammatory disorders of the CNS that often present with a relapsing remitting course and are characterized by optic neuritis and longitudinally extensive transverse myelitis. They are typically associated with serum antibodies that selectively bind to AQP4 or myelin oligodendrocyte glycoprotein 2 (MOG). 1 The discovery of pathogenic AQP4-Ab resulted in expansion of the clinical phenotypes associated with NMSODs to include patients with more atypical neuroinflammation even in the absence of optic neuritis and transverse myelitis, but who test positive for these antibodies. Notably, in recent years, growing evidence suggests that AQP4-IgG may also causes damage to peripheral AQP4-expressing organs beyond the CNS such as skeletal muscle, vestibulocochlear nerves, gastrointestinal tract, blood system, kidney, lung and placent. 2 So the spectrum of disease associated with these autoantibodies may expand over the years.
Notably, the presence of AQP4-Ab has already been described in the context of systemic autoimmune diseases such as adult onset systemic lupus erythematosus (SLE) [4] [5] [6] but no studies have systematically assessed the presence of AQP4-Ab in children and adolescents with juvenile onset systemic lupus erythematosus (jSLE). While jSLE shares clinical and serological features with adultonset SLE, jSLE typically exhibits a much more severe protracted disease course. Notably, the incidence of neuropsychiatric manifestations in jSLE is much more common than in adult patients. 7 Whether this increased frequency of neurological manifestations in paediatric patients relates to the presence of neurotoxic antibodies such as AQP4-Ab remains unclear.
The aim of this study was therefore to: (a) screen a large group of unselected patients with jSLE for AQP4-Ab; (b) identify clinical and laboratory predictors of presence of AQP4-Ab positivity in jSLE.
Methods
We screened for the presence of AQP4-Ab a total of 90 patients with jSLE fulfilling the 1997 American College of Rheumatology (ACR) criteria 8 seen in the paediatric and adolescent rheumatology and paediatric neurology departments at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London Hospitals between 2009 and 2017. Ethical approval for the study was obtained from the regional ethical committee (study reference 16IR33).
AQP4-IgG antibodies were measured in serum using a validated commercially available cellbased assay (Euroimmun, UK) as per the manufacturer's instructions. 9 In addition, testing for MOG antibodies was also completed for those patients with positive AQP4-Ab. The demographic, clinical and laboratory characteristics recorded were as follows: sex, age, ethnicity (established by way of the information provided by patients/parents to register with the hospital), neurological symptoms, previous organ involvement, manifestations of jSLE, erythrocyte sedimentation rate (ESR, in the first hour; normal <10 mm/hour) and serum CRP (normal range <10 mg/L), presence of anti-dsDNA antibodies (normal range 0-9.9 IU/ml), anti-nuclear antibodies (ANA), antibodies to ENA and its subtypes, antiphospholipid antibodies (aPL), lupus anticoagulant (LA) and complement C3 and C4 levels. The therapies used were also recorded.
Statistical analysis was performed using SPSS (SPSS Inc., Chicago, IL, USA). Fisher's exact test was used for comparison between groups. Categorical data were summarized as percentages. Any continuous variables were summarized as median and range. Two-sided P values less than 0.05 were considered significant.
Results
We studied a total of 90 patients (11/90, 12% male) with jSLE with a median age of 18.7 (range 11-27) years. Nineteen out of 90 (21%) were white British, 11/90 (12%) white other, 3/90 (3%) black British, 7/90 (8%) black African, 11/90 (12%) black Caribbean, 24/90 (27%) Asian, 15/90 (17%) of mixed background or of other or unknown ethnicity. The median age of disease onset was 8 (range 0.3-15) years.
Five out of 90 patients tested positive for AQP4-Ab. All patients but one who tested positive for AQP4-IgG at diagnosis remained positive on repeat measurements during follow-up: median three measurements (range 1-8) over a median of 18.5 (range 9-20) months. Table 1 summarizes the clinical characteristics of the five patients who tested positive for AQP4-Ab at the time of initial presentation and latest followup, brain MRI findings and treatment received. These five patients had a median age of 15 (range 11-17.5) years; a median disease duration of 3 (range 0.2-8.5) years, and a median length of follow-up of 3 (range 1-9) years.
A predominant neurological presentation was observed in three out of five (60%) at onset, with the other two developing neurological symptoms over time. Four out of five (80%) patients fulfilled Aquaporin-4 IgG antibody-related disorders in jSLE E Moraitis et al. Table 1 ). 10 MOG antibodies tested negative in five out ot five patients. Two out of four patients with spinal lesions had recurrence of transverse myelitis and optic neuritis on more than one occasion (Figure 1) . One child presented with acute psychosis, in the context of normal neuroimaging. Cerebrospinal fluid (CSF) analysis was performed in two patients. CSF was acellular, with normal protein and no detection of CSF oligoclonal bands.
Treatment received included corticosteroids in all patients; cyclophosphamide (2/5); rituximab (3/5); plasma exchange (2/5); azathioprine (3/5) and mycophenolate mofetil (MMF) (2/5).
Predictors of the presence of AQP4-Ab in jSLE
Patients with positive AQP4-Ab were more likely to have neurological involvement compared to those who tested negative (P ¼ 0.002), and they were less likely to have skin involvement (P ¼ 0.045) Aquaporin-4 IgG antibody-related disorders in jSLE E Moraitis et al.
( Table 2 ). There appeared to be no other significant differences between groups of patients when the remaining clinical features were considered. Patients with positive AQP4-Ab were less likely to have positive anti-dsDNA antibodies than those with negative AQP4-Ab (P ¼ 0.022) ( Table 2) , with no other significant differences between the two groups of patients when the remaining laboratory characteristics were considered.
All treatments received prior to the sample collection were included in the analysis. Patients with AQP4-Ab antibodies were more likely to receive anti-epileptics (P ¼ 0.023) and anti-coagulants (P ¼ 0.007), and they were less likely to have received hydroxychloroquine (P < 0.001) ( Table 2 ).
Discussion
In this retrospective case series, we have shown that there is a subgroup of patients with jSLE that develops AQP4-Ab and these patients are more likely to develop neurological involvement. The main clinical phenotype associated with AQP4-IgG seropositivity was transverse myelitis and optic neuritis. We would recommend that clinicians have a low threshold for screening for the presence of these antibodies in patients with jSLE and have a low threshold for undertaking neuroimaging investigations to screen for neurological involvement.
A previous study in adults with SLE that systematically assessed for the presence of anti-AQP4-IgG antibodies in a large cohort of patients indicated that only SLE patients with NMOSD features tested positive for these antibodies. 4 These results were therefore supportive of the specificity of a positive test for AQP4-Ab rather than this being an epiphenomenon of autoimmunity, and were highlighting a unique neurological clinical phenotype in SLE. We now also demonstrate that younger patients with jSLE may also develop these antibodies and are also at risk of neurological involvement.
We note the lack of classic NMOSD clinical features in one patient positive for AQP4-Ab. This patient, however, had already received significant immunosuppressive treatment for other jSLE features at the time of AQP4-Ab testing, which may have influenced his clinical presentation. Although false positivity cannot be ruled out, it is possible that NMOSD symptomatology may differ in patients with established autoimmunity. Alternatively, antibody positivity may precede the onset of a severe neurological phenotype similar to reports in the case of patients with myasthenia gravis.
11
The therapeutic approach with respect to immunosuppression did not differ between groups and this is unsurprising as rituximab, cyclophosphamide and corticosteroids are effective therapies for NMOSDs as well as SLE. The patients with AQP4-Ab positivity were less likely to be treated with hydroxychloroquine. Although hydroxychloroquine is a safe drug and generally recommended for the treatment of all patients with SLE, 12 the decreased use in patients with AQP4-Ab positivity could reflect the reluctance of clinicians to add a medication with a risk of retinal toxicity to the patients with optic neuritis.
We acknowledge the retrospective nature of our cohort and likely bias by case severity as patients were included from two tertiary centres. Larger prospective longitudinal studies are now needed to confirm our observations and to establish whether AQP4-Ab are persistent or transient and the effect of immunotherapy on these antibodies. In our study we used a qualitative assay for the detection of anti-AQP4-Ab; future studies using quantitative assays and temporal correlation with the clinical status would be of interest. Nevertheless, our results highlight the association between jSLE and AQP4 autoimmunity, and support the screening for these antibodies in all patients with jSLE to establish the risk of neurological involvement.
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